No Data
No Data
Express News | Plus Therapeutics Files for Mixed Shelf Offering of up to $100 Mln- SEC Filing
Buy Rating Affirmed for Plus Therapeutics Amidst ReSPECT-GBM Trial Progress and Overlooked Market Potential
Plus Therapeutics' Rhenium Obisbemeda Shows Safety, Potential Efficacy
Express News | Plus Therapeutics Presented An Update On Ongoing ReSPECT-GBM Phase 1/2 Trial Of The Company's Lead Asset Rhenium (186Re) Obisbemeda For Recurrent Glioblastoma
12 Health Care Stocks Moving In Friday's Intraday Session
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
No Data
No Data
151479178 : Do you know why *the price has recently/ is fluctuating so much?